Table 3 Univariate analysis of mutated genetic pathways, DDR genes, and recurrence survival rate
Genetic pathway | Total patients (n = 58) | BCG subgroup (n = 46) | ||
|---|---|---|---|---|
P-value | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | |
Qualitative | ||||
Epigenetic-related genes | 0.020 | 0.278 (0.095–0.814) | 0.023 | 0.198 (0.049–0.797) |
TP53/cell cycle pathway | 0.668 | 0.805 (0.299–2.170) | 0.725 | 0.790 (0.212–2.942) |
RTK-PI3K pathway | 0.830 | 0.849 (0.192–3.765) | 0.351 | 0.473 (0.098–2.280) |
SWI/SNF pathway | 0.182 | 0.424 (0.120–1.497) | 0.397 | 0.507 (0.105–2.439) |
DNA damage pathway | 0.554 | 0.710 (0.229–2.204) | 0.965 | 0.969 (0.242–3.878) |
Alternative splicing pathway | 0.059 | 0.240 (0.054–1.056) | 0.289 | 0.427 (0.089–2.056) |
DDR genes | 0.298 | 2.931 (0.387–22.211) | 0.632 | 1.662 (0.208–13.306) |
Quantitative | ||||
Epigenetic-related genes | 0.960 | 0.993 (0.756–1.303) | 0.877 | 1.030 (0.710–1.494) |
TP53/cell cycle pathway | 0.942 | 1.016 (0.665–1.553) | 0.958 | 0.985 (0.566–1.716) |
RTK-PI3K pathway | 0.096 | 0.686 (0.440–1.069) | 0.308 | 0.756 (0.441–1.295) |
SWI/SNF pathway | 0.170 | 0.567 (0.252–1.275) | 0.379 | 0.671 (0.276–1.632) |
DNA damage pathway | 0.319 | 0.700 (0.348–1.411) | 0.582 | 0.810 (0.382–1.716) |
Alternative splicing pathway | 0.101 | 0.400 (0.134–1.195) | 0.410 | 0.629 (0.208–1.897) |
DDR genes | 0.603 | 0.951 (0.788–1.148) | 0.808 | 0.974 (0.789–1.203) |